The small G protein Rap 1 in Tau cell activation/anergy
Tau 细胞激活/无反应中的小 G 蛋白 Rap 1
基本信息
- 批准号:6327005
- 负责人:
- 金额:$ 30.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-03-15 至 2006-02-28
- 项目状态:已结题
- 来源:
- 关键词:CD28 molecule CD3 molecule T cell receptor T lymphocyte anergy genetically modified animals guanine nucleotide binding protein guanosinetriphosphatases interleukin 2 laboratory mouse leukocyte activation /transformation mitogen activated protein kinase protein biosynthesis tissue /cell culture transfection
项目摘要
DESCRIPTION (Provided by the Applicant): A productive T lymphocyte response to
antigen requires the activation of two signaling pathways, involving signals
generated by the interactions between the T-cell receptor (TCR) with antigenic
peptide presented on antigen-presenting cells (APCs) and the signal mediated by
the binding of the accessory receptor CD28 with its ligand B7. Although the
requirement for CD28 co-stimulation has been the subject of intensive and
extensive investigation, the molecular nature of this co-stimulatory signal is
unknown. Some models have identified distinct kinase cascades initiated by
either the ICR or CD28, while other models have focused on the convergence of
TCR/CD28 signals on particular kinase cascades. One pathway which can mediate
the synergistic responses that characterize CD28 co-stimulation is the MAP
kinase (ERK) cascade. The activation of the MAP kinase ERK following CD28
co-stimulation is required for IL-2 production and proliferation of responding
T lymphocytes. ERK activation in T lymphocytes is regulated by two antagonistic
small G proteins: Ras and Rap1. Ras activation is required for ERK activation,
while Rap1 antagonizes Ras signaling. Antigen recognition by T-cells in the
absence of CD28 co-stimulation is characterized by impaired ERK activation and
both decreased IL-2 production and diminished proliferation. This functional
unresponsiveness results in the inability to respond to subsequent
co-stimulatory signals and is termed clonal anergy. Rap1 is constitutively
activated in certain states of I cell anergy or this unresponsiveness may
account for the diminished ERK activity and decreased IL-2 production seen in
anergic T-cells. In this proposal, we will test the hypothesis that Rap1 is
activated by ICR ligation in normal I cells and consequently limits I cell
activation through the ICR in the absence of co-stimulation. In addition, we
will test the hypothesis that CD28 co-stimulation achieves increased ERK
activation, IL-2 production and proliferation by blocking Rap1 activation.
描述(由申请人提供):生产性T淋巴细胞对
抗原需要激活两个信号途径,涉及信号
由T细胞受体(TCR)与抗原之间的相互作用产生
在抗原呈递细胞(APC)上呈现的肽和由
辅助受体CD28与其配体B7的结合。虽然
CD28共同刺激的需求一直是密集的主题
广泛的研究,该共刺激信号的分子性质是
未知。一些模型已经确定了由
ICR或CD28,而其他模型则集中于
特定激酶级联反应的TCR/CD28信号。一条可以调节的途径
表征CD28共刺激的协同响应是地图
激酶(ERK)级联。 CD28之后的MAP激酶ERK的激活
IL-2产生和响应的扩散需要共刺激
T淋巴细胞。 T淋巴细胞中的ERK激活受两个拮抗作用调节
小G蛋白:RAS和RAP1。 ERK激活需要RAS激活,
Rap1拮抗RAS信号传导。 T细胞在
CD28共刺激的缺乏的特征是ERK激活受损和
两者都降低了IL-2的产生,并减少了增殖。这个功能
无反应性导致无法应对随后的
联合刺激信号,称为克隆语。 Rap1是组成型
在某些I细胞消极的状态或这种不响应的状态中激活
占ERK活性降低并减少IL-2产生的原因
厌食症的T细胞。在此提案中,我们将测试Rap1是
通过正常I细胞中的ICR连接激活,因此限制了I细胞
在没有共刺激的情况下通过ICR激活。另外,我们
将测试CD28共刺激实现ERK的假设
通过阻断RAP1激活,激活,IL-2产生和增殖。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIP J.S. STORK其他文献
PHILIP J.S. STORK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIP J.S. STORK', 18)}}的其他基金
Spatial control of cAMP signaling by Epacs
Epacs 对 cAMP 信号传导的空间控制
- 批准号:
8181877 - 财政年份:2011
- 资助金额:
$ 30.2万 - 项目类别:
Spatial control of cAMP signaling by Epacs
Epacs 对 cAMP 信号传导的空间控制
- 批准号:
8320237 - 财政年份:2011
- 资助金额:
$ 30.2万 - 项目类别:
Spatial control of cAMP signaling by Epacs
Epacs 对 cAMP 信号传导的空间控制
- 批准号:
8502657 - 财政年份:2011
- 资助金额:
$ 30.2万 - 项目类别:
Spatial control of cAMP signaling by Epacs
Epacs 对 cAMP 信号传导的空间控制
- 批准号:
8685251 - 财政年份:2011
- 资助金额:
$ 30.2万 - 项目类别:
Modulation of Intracellular Signaling in Cardiac Hypertrophy
心脏肥大中细胞内信号传导的调节
- 批准号:
7298850 - 财政年份:2007
- 资助金额:
$ 30.2万 - 项目类别:
The small G protein Rap 1 in T cell activation/anergy
T 细胞激活/无反应中的小 G 蛋白 Rap 1
- 批准号:
6632272 - 财政年份:2001
- 资助金额:
$ 30.2万 - 项目类别:
The small G protein Rap 1 in T cell activation/anergy
T 细胞激活/无反应中的小 G 蛋白 Rap 1
- 批准号:
6511270 - 财政年份:2001
- 资助金额:
$ 30.2万 - 项目类别:
The small G protein Rap 1 in T cell activation/anergy
T 细胞激活/无反应中的小 G 蛋白 Rap 1
- 批准号:
6867359 - 财政年份:2001
- 资助金额:
$ 30.2万 - 项目类别:
The small G protein Rap 1 in T cell activation/anergy
T 细胞激活/无反应中的小 G 蛋白 Rap 1
- 批准号:
6706955 - 财政年份:2001
- 资助金额:
$ 30.2万 - 项目类别:
相似海外基金
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics
开发具有单一特异性和改善持久性的细胞治疗产品,以防止对生物治疗药物的免疫
- 批准号:
10726703 - 财政年份:2023
- 资助金额:
$ 30.2万 - 项目类别:
Function- and interaction-based discovery of negative allosteric modulators of the A2A Receptor
基于功能和相互作用的 A2A 受体负变构调节剂的发现
- 批准号:
10355152 - 财政年份:2022
- 资助金额:
$ 30.2万 - 项目类别:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
用于治疗应用的仿生刺激器的工程和测试
- 批准号:
10705808 - 财政年份:2022
- 资助金额:
$ 30.2万 - 项目类别:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
用于治疗应用的仿生刺激器的工程和测试
- 批准号:
10570359 - 财政年份:2022
- 资助金额:
$ 30.2万 - 项目类别:
Function- and interaction-based discovery of negative allosteric modulators of the A2A Receptor
基于功能和相互作用的 A2A 受体负变构调节剂的发现
- 批准号:
10625971 - 财政年份:2022
- 资助金额:
$ 30.2万 - 项目类别: